Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 18 · below the Ichimoku cloud · RSI 44 · MACD below its signal
None of the 29 investors followed here reported a position in AXIM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AXIM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for AXIM.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 36.4 | -26.7 | -45.5 | 0.0 | 0.0 | -50.0 | 0.0 | 33.3 | -25.0 | 0.0 | −72.7% | ||
| 2025 | 100.0 | -25.0 | 33.3 | 75.0 | 0.0 | -14.3 | 0.0 | -16.7 | 0.0 | 100.0 | 100.0 | -45.0 | +450.0% |
| 2024 | 5.3 | -35.0 | -7.7 | 25.0 | -40.0 | 11.1 | 40.0 | -50.0 | -28.6 | 0.0 | -60.0 | 0.0 | −89.5% |
| 2023 | -10.7 | -28.0 | 27.8 | 21.7 | -25.0 | 52.4 | -6.3 | -23.3 | -8.7 | -14.3 | 0.0 | 5.6 | −32.1% |
| 2022 | -51.5 | 31.0 | -53.8 | -41.7 | -12.2 | -13.8 | -28.6 | 125.0 | 11.1 | -21.0 | -40.5 | -40.4 | −93.5% |
| 2021 | -3.0 | 60.0 | -0.3 | -25.4 | 58.0 | 18.9 | -24.0 | -13.3 | -9.5 | -27.3 | -9.1 | 17.0 | 0.0% |
| 2020 | -5.2 | -45.1 | -28.9 | 2.2 | 189.9 | -32.8 | 171.4 | -13.0 | -4.3 | -26.0 | -4.4 | 0.7 | +18.6% |
| 2019 | 30.7 | 59.2 | -4.5 | -16.1 | -28.8 | -7.9 | -13.4 | -8.5 | 0.0 | -22.8 | -15.3 | -14.1 | −51.3% |
| 2018 | -24.3 | -23.3 | -36.6 | 30.0 | -24.7 | -15.0 | -27.9 | 9.8 | -17.2 | -17.5 | -34.6 | -25.0 | −91.9% |
| 2017 | 61.3 | -30.5 | 37.9 | -14.0 | -11.5 | -1.8 | -20.4 | -19.2 | 3.7 | -0.7 | 5.5 | 31.9 | +6.3% |
| 2016 | 163.3 | -49.4 | 0.0 | 22.5 | -8.2 | -18.0 | -10.6 | -7.6 | -24.6 | 1073.9 | 212.6 | 3.1 | +2800.0% |
| 2015 | 0.0 | 0.0 | -87.0 | -23.1 | -1.0 | -4.0 | -15.8 | -25.0 | 16.7 | -41.4 | -2.4 | -25.0 | −97.0% |
| 2014 | 0.0 | 0.0 | 0.0 | 0.0% |
No analyst coverage for this instrument.
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.